You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
俄驻华大使:中国疫苗在俄临床初步结果「非常好」
阿思达克 12-30 10:00
据《北京晚报》报道,在俄罗斯驻华使馆昨日(29日)举行的2020年年度新闻发布会上,驻华大使安德烈-杰尼索夫表示,中国供应商提供的医疗物资帮助俄罗斯渡过了疫情发生以来最困难的时期,中国公司在俄罗斯进行疫苗临床试验,试验结果「非常好」。

杰尼索夫介绍了两国在新冠疫苗领域的合作情况。他表示,疫苗涉及到非常复杂的研究和技术,在国际合作惯例当中,疫苗合作非常少见。

他表示,俄中两国在新冠疫苗领域开展务实合作。中国康希诺生物(06185.HK)研制的疫苗是第一个获得俄罗斯卫生部许可,在俄罗斯进行临床试验的疫苗。8,000名志愿者接受了临床试验,目前相关试验已经完成,正在对数据进行分析。根据俄方了解,初步的试验结果非常好。

杰尼索夫还透露,俄罗斯方面还与中国医疗机构合作,计划在中国生产俄罗斯新冠疫苗「卫星V」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account